An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-201728182564
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD Science Committee report 2019. Eur Respir J. 2019;53:1900164. doi:10.1183/13993003.00164-201930846476
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14(1):178. doi:10.1186/1471-2466-14-17825404569
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15(1):123. doi:10.1186/s12931-014-0123-025756831
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92. doi:10.1186/s12931-015-0250-226233481
   PubMed Web of Science ®Google Scholar
• AstraZeneca PLC. Duaklir® Genuair™ Summary of Product Characteristics. 2018 Available from: http://www.medicines.org.uk/emc/medicine/29652 Accessed 622, 2018.
   Google Scholar
• Leidy NK, Murray LT, Monz BU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15(1):124. doi:10.1186/s12931-014-0124-z25287629
   PubMed Web of Science ®Google Scholar
• Hareendran A, Palsgrove AC, Mocarski M, et al. The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:104. doi:10.1186/1477-7525-11-10423799883
   PubMed Web of Science ®Google Scholar
• Mocarski M, Zaiser E, Trundell D, Make BJ, Hareendran A. Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis. 2015;10:475–487. doi:10.2147/COPD.S7577625834415
   PubMed Web of Science ®Google Scholar
• Mocarski M, Hareendran A, Jen MH, Zaiser E, Make B. Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI). Value Health. 2014;17:A179.
   Web of Science ®Google Scholar
• Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/COPD-20005051317136966
   PubMedGoogle Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. doi:10.1081/COPD-20005337717136971
   PubMedGoogle Scholar
• Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103. doi:10.1081/COPD-20005066617136969
   PubMedGoogle Scholar
• Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-324621681
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33(12):2188–2199. doi:10.1007/s12325-016-0430-627796912
   PubMed Web of Science ®Google Scholar
• Lange P, Godtfredsen NS, Olejnicka B, et al. Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting. Eur Clin Respir J. 2016;3:31232. doi:10.3402/ecrj.v3.3123227387608
   PubMed Web of Science ®Google Scholar
• Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO(R) studies. Respir Res. 2016;17(1):73. doi:10.1186/s12931-016-0387-727316465
   PubMed Web of Science ®Google Scholar
• Sauer R, Hansel M, Buhl R, Rubin RA, Frey M, Glaab T. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis. 2016;11:891–898. doi:10.2147/COPD.S10302327217742
   PubMed Web of Science ®Google Scholar
• Setoguchi Y, Izumi S, Nakamura H, et al. Survey to determine the efficacy and safety of guideline-based pharmacological therapy for chronic obstructive pulmonary disease patients not previously receiving maintenance treatment. Expert Opin Pharmacother. 2015;16(15):2271–2281. doi:10.1517/14656566.2015.107467826290277
   PubMed Web of Science ®Google Scholar
• Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003. doi:10.1038/npjpcrm.2014.324841833
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Fabbri LM, Rabe KF, et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respir Med. 2013;107(1):75–83. doi:10.1016/j.rmed.2012.09.01523102611
   PubMed Web of Science ®Google Scholar
• Decramer M, Rossi A, Lawrence D, McBryan D. Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respir Med. 2012;106(12):1706–1714. doi:10.1016/j.rmed.2012.08.02223031496
   PubMed Web of Science ®Google Scholar
• Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010;36(1):65–73. doi:10.1183/09031936.0012780920185426
   PubMed Web of Science ®Google Scholar
• [Guideline for diagnosis and management of COPD (chronic obstructive pulmonary disease). The Third Edition: therapy and management]. Nihon Kokyuki Gakkai Zasshi. 2009;Suppl COPD:70–144. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22712100. Accessed November 19, 2019.
   Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP24383418
   PubMed Web of Science ®Google Scholar
• Price D, Miravitlles M, Pavord I, et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med. 2016;26:16061. doi:10.1038/npjpcrm.2016.6127808096
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-030343028
   PubMed Web of Science ®Google Scholar
• Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336–349. doi:10.1111/ijcp.2015.69.issue-325363328
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/COPD22371650
   PubMed Web of Science ®Google Scholar